CGT Global And Octomera Enter Agreement To Expand Cell & Gene Therapy Development And Patient Access Across The United States
Portfolio Pulse from Benzinga Newsdesk
Orgenesis Inc. (NASDAQ:ORGS) is expanding its cell and gene therapy development and patient access across the US through its subsidiary Octomera, in partnership with CGT Global. The collaboration aims to leverage CGT Global's network of CGT Clinics and healthcare partnerships to commercialize CGTs in California and other US locations. The companies plan to align resources to place Octomera Mobile Processing Units & Labs (OMPULs) for leukapheresis and the production of CAR-T and TILS products. The partnership is expected to grow as CGT Global currently partners with 32 hospitals and anticipates partnering with over 200 hospitals by the end of 2024.
September 21, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Orgenesis Inc. is expanding its cell and gene therapy development and patient access across the US through a partnership with CGT Global. This collaboration could potentially increase the company's market reach and revenue.
The partnership with CGT Global allows Orgenesis to leverage an extensive network of CGT Clinics and healthcare partnerships, which could potentially increase its market reach and revenue. The plan to align resources for the production of CAR-T and TILS products could also lead to an increase in the company's product offerings, potentially attracting more customers and generating more revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100